0001640334-26-000574
SEC filingArtelo Biosciences completed a $11.0 million private placement on March 30, 2026, issuing shares and warrants to accredited investors, with proceeds intended for working capital, debt repayment, and general corporate purposes.
Artelo Biosciences has secured approximately $11.0 million in gross proceeds through a private placement to accredited investors, providing critical capital for operations and debt repayment. The financing structure includes both immediate equity through common stock and pre-funded warrants, along with longer-term potential equity through common warrants exercisable at $3.20 per share. The company's placement agent, H.C. Wainwright & Co., received standard compensation including an 8.0% cash fee and warrants. Importantly, the company has committed to registering the securities for resale, with specific filing and effectiveness deadlines that provide investors with potential liquidity. The transaction appears strategically timed to address the company's Nasdaq listing compliance concerns, as the net proceeds of approximately $10.0 million are expected to bring stockholders' equity above the $2.5 million minimum requirement. However, the company acknowledges there is no assurance Nasdaq will determine compliance has been achieved. The offering's structure, with both immediate and potential future equity components, provides the company with current capital while offering investors participation in potential future stock appreciation through the warrants.